Showing 631-640 of 5061 results for "".
- AMA: New CPT Code to Report Novel Coronavirus Testhttps://practicaldermatology.com/news/ama-new-cpt-code-to-report-novel-coronavirus-test/2460307/The Current Procedural Terminology (CPT®)Editorial Panel has approved a new addition to the CPT code set to report testing for the virus that causes COVID-19. The American Medical Association (AMA) says the code will help streamline data-driven resource and allocation planning in t
- International Psoriasis Council Offers Guidance on Managing COVID-19 in People with Psoriasishttps://practicaldermatology.com/news/international-psoriasis-council-offers-guidance-on-managing-covid-19-in-people-with-psoriasis/2460302/Psoriasis patients diagnosed with COVID-19 (coronavirus disease) should immediately discontinue or postpone immunosuppressant medications, guidance from the International Psoriasis Council (IPC) states. The group cites current guidance from the European Dermatology Forum and the American Academy
- Revance: FDA Accepts BLA for DaxibotulinumtoxinA, Sets November PDUFA Datehttps://practicaldermatology.com/news/revance-fda-accepts-bla-for-daxibotulinumtoxina-sets-november-pdufa-date/2460278/FDA has accepted the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar (frown) lines, Revance reports. The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
- South Beach Symposium Poised for 18th Miami Conferencehttps://practicaldermatology.com/news/south-beach-symposium-poised-for-18th-miami-conference/2460253/The 18th Annual South Beach Symposium takes place in Miami Beach next month. Organizers say the annual conference boasts an extensive agenda, with in-depth pre-conference offerings, and sessions topics covering the latest and most well-supported knowledge in clinical and aesthetic dermatology. Ro
- Norfolk Dermatologist Recognized for Increasing Accessibility for Patientshttps://practicaldermatology.com/news/norfolk-dermatologist-recognized-for-increasing-accessibility-for-patients/2460227/Dermatologist Abby Van Voorhees, MD, FAAD, is an American Academy of Dermatology Patient Care Hero for her leadership at the Rapid Access Clinic at the Eastern Virginia Medical School Dermatology Practice in Norfolk, Va. The Eastern Virginia Medical School Dermatology practice allo
- Celebrate National Botox Day on November 20, 2019https://practicaldermatology.com/news/celebrate-national-botox-day-on-november-20th-2019/2460218/Mark your calendars: November 20, 2019 will be the first-ever National Botox Cosmetic Day. Why Nov. 20? It is the busiest day on record for booking Botox cosmetic treatments in the US. And to commemorate it, Allergan is offering an exclusive deal for one day only where patien
- Arcutis Biotherapeutics Plans to Initiate Phase 3 Program for ARQ-151 for Plaque Psoriasishttps://practicaldermatology.com/news/arcutis-biotherapeutics-plans-to-initiate-phase-3-program-for-arq-151-for-plaque-psoriasis/2460196/Arcutis Biotherapeutics, Inc. plans to initiate its Phase 3 program of ARQ-151 as a potential topical treatment for plaque psoriasis following its End-of-Phase 2 meeting with the FDA. The Company anticipates initiating a Phase 3 clinical trial in the first half of 2020. Frank Watanabe,
- Verrica Pharmaceuticals: Positive Data for VP-102 for Molluscum Contagiosum, Wartshttps://practicaldermatology.com/news/verrica-pharmaceuticals-positive-data-for-vp-102-for-molluscum-contagiosum-warts/2460187/Positive data for VP-102 (cantharidin 0.7% Topical Solution) from Verrica Pharmaceuticals, Inc. are being presented in poster form at the Annual Fall Clinical Dermatology Conference in Las Vegas. Company’s lead product candidate is being developed for the treatment of molluscum c
- Research Substantiates Psoriasis/Non-alcoholic Fatty Liver Disease Linkhttps://practicaldermatology.com/news/research-substantiates-psoriasisnon-alcoholic-fatty-liver-disease-link/2460174/The severity of psoriasis is related to the severity of non-alcoholic fatty liver disease (NAFLD), according to research presented at the 28th European Dermato-Venereology Society Congress in Madrid. Patients with psoriasis and NAFLD had more severe hepatic damage if they had a higher s
- Positive Results for Aclaris Therapeutics’ A-101 45% Topical Solution in Pivotal Phase 3 Trial for the Treatment of Wartshttps://practicaldermatology.com/news/positive-results-for-aclaris-therapeutics-a-101-45-topical-solution-in-pivotal-phase-3-trial-for-the-treatment-of-warts/2460151/Aclaris Therapeutics, Inc., shared positive results from its Phase 3 clinical trial, THWART-2 (WART-302), of A-101 45% Topical Solution, an investigational new drug for the treatment of common warts (verruca vulgaris). A-101 45% Topical Solution met the